PP-048
PP-048 is a selective dual inhibitor of Polθ/PARP1, with IC50 values of 4.9 nM and 6.8 nM for the Polθ helicase/ATPase domain and PARP1, respectively. PP-048 impairs the compensatory DNA repair capacity of homologous recombination-deficient cells by simultaneously inhibiting the DNA repair functions associated with Polθ and PARP1, thereby exacerbating DNA double-strand damage and inducing apoptosis. PP-048 exhibits more potent selective antiproliferative activity against HR-deficient cancer cells. PP-048 can be used in studies related to Polθ/PARP1 dual-target inhibition, synthetic lethality, DNA damage repair, and HR-deficient triple-negative breast cancer.
For research use only. We do not sell to patients.
- Formula: C37H33ClN10O3S
- Molecular Weight:733.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PARP1 6.8 nM (IC50) |
Polθ 4.9 nM (IC50) |
PARP2 1542 nM (IC50) |
PARP3 3340 nM (IC50) |
PARP5A 8266 nM (IC50) |
PARP5B 7986 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-436 | IC50 |
0.07 μM
|
Antiproliferative activity against BRCA1-deficient MDA-MB-436 cells assessed by CCK-8 assay after 7 days of incubation.
Antiproliferative activity against BRCA1-deficient MDA-MB-436 cells assessed by CCK-8 assay after 7 days of incubation.
|
acs.jmedchem.6c01400 |
| HCT-116 | IC50 |
5.0 μM
|
Antiproliferative activity against BRCA2-knockout HCT116 cells assessed by CCK-8 assay after 7 days of incubation.
Antiproliferative activity against BRCA2-knockout HCT116 cells assessed by CCK-8 assay after 7 days of incubation.
|
acs.jmedchem.6c01400 |
| MDA-MB-231 | IC50 |
68.4 μM
|
Antiproliferative activity against BRCA-proficient MDA-MB-231 cells assessed by CCK-8 assay after 7 days of incubation.
Antiproliferative activity against BRCA-proficient MDA-MB-231 cells assessed by CCK-8 assay after 7 days of incubation.
|
acs.jmedchem.6c01400 |
In Vitro
PP-048 inhibits the ATPase activity of the recombinant human Polθ helicase domain, with an IC50 of 4.9 nM[1].
PP-048 (10 nM-100 nM; 60 min) inhibits the enzymatic activity of full-length recombinant human PARP1, with an IC50 of 6.8 nM[1].
PP-048 (10 nM-100 μM; 1 h) exhibits a selectivity for PARP1 that is more than 226-fold higher than that for PARP2, PARP3, PARP5a, PARP5b, and PARP7, with IC50 values against these corresponding off-target isoforms of 1542 nM, 3340 nM, 8266 nM, 7986 nM, and >100000 nM, respectively[1].
PP-048 (5 μM; 2 h) simultaneously binds to PARP1 and Polθ in MDA-MB-436 cells and enhances their thermal stability, confirming its dual-target binding property in living HR-deficient cancer cells[1].
PP-048 (1.0 μM; 0-45 min) exhibits excellent metabolic stability in human liver microsomes, with a half-life of 254.47 min and an intrinsic clearance of 6.30 mL/min/kg[1].
PP-048 (1.0 μM; 0-60 min) exhibits excellent metabolic stability in rat liver microsomes, with a half-life of 347.22 min and an intrinsic clearance of 4.62 mL/min/kg[1].
PP-048 (10 μM; 120 min) exhibits low passive permeability across Caco-2 cell monolayers, with an efflux ratio as high as 75.83, indicating that PP-048 is a potential P-gp substrate[1].
PP-048 (0.5 μM; 72 h) significantly increases the number of γH2AX foci and fluorescence intensity in MDA-MB-436 cells[1].
PP-048 (0.1 and 0.5 μM; 72 h) increases γH2AX protein levels in a dose-dependent manner[1].
PP-048 (up to 80 μM; 7 days) exhibits potent antiproliferative activity against HR-deficient MDA-MB-436 cells, with an IC50 of 0.07 μM; it shows moderate activity against BRCA2-knockout HCT116 cells, significantly reduced potency against HR-proficient MDA-MB-231 cells, and no obvious activity against non-malignant MCF-10A cells[1].
PP-048 (0.5 μM; 9 days) almost completely inhibits the clonogenic survival of MDA-MB-436 BRCA1-deficient cells after 9 days of incubation[1].
PP-048 (0.5 μM; 72 h) induces significant apoptosis in MDA-MB-436 BRCA1-deficient cells after 3 days of incubation, and its effect is superior to that of two single-target reference inhibitors at their respective tested concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-436
-
Concentration:0.5 μM
-
Incubation Time:9 days
-
Result:Almost completely suppressed colony formation.
-
Cell Line:MDA-MB-436
-
Concentration:0.5 μM
-
Incubation Time:72 h
-
Result:Induced a higher level of apoptosis in MDA-MB-436 cells than treatment with reference compounds.
Increased the total apoptotic population to 22% following exposure.
-
Cell Line:MDA-MB-436
-
Concentration:0.1, 0.5 μM
-
Incubation Time:72 h
-
Result:Dose-dependently increased γH2AX protein levels.
Parmacokinetics
In Vivo
PP-048 (1-10 mg/kg; intravenous injection; oral administration; single dose) exhibits significantly improved in vivo pharmacokinetic properties in healthy Sprague-Dawley rats, with an oral bioavailability of up to 12.7%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (Five-week-old female, 18-20 g)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; once daily; 21 consecutive days
-
Result:Achieved 91.3% TGI.
Produced greater tumor growth inhibition than AB25583 alone (TGI 11%).
Produced greater tumor growth inhibition than AZD5305 alone (TGI 75.2%).
Produced greater tumor growth inhibition than the AB25583 + AZD5305 group (TGI 81.2%).
Maintained stable body-weight changes during administration.
Showed no discernible histopathological toxicity in the heart, liver, spleen, lungs, or kidneys.
Markedly increased γH2AX expression in harvested tumor tissues.
Produced stronger tumor γH2AX staining than AB25583, AZD5305, or their combined administration.
Did not produce obvious reductions in terminal platelet counts.
Did not produce obvious reductions in terminal red blood cell counts.
Chemical Information
-
Molecular Weight 733.24
-
Formula C37H33ClN10O3S
-
SMILES
CCC1=CC2=C(NC1=O)C=C(C=N2)CN3CCN(CC3)C4=CN=C(C=C4)C#CC5=NN=C(S5)NC(C6=C(C=C(N=C6)C)C7=CC(Cl)=NC=C7OC)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
CRISPR-Cas9 HDR knock-in/precise editing
CRISPR-Cas9 HDR knock-in uses a guide RNA to direct Cas9 to a genomic target adjacent to a PAM, where Cas9 creates a double-strand break; if a donor DNA template with homology to the cut region is present, cellular HDR can copy the donor sequence into the genome, producing a precise substitution, tag, reporter, or insertion rather than an indel. The readout is the fraction of alleles or cells carrying the intended donor-derived edit, measured by junction PCR, restriction-fragment analysis, Sanger sequencing, amplicon deep sequencing, flow cytometry for reporter knock-in, or clone genotyping; NHEJ indels and partial or non-HDR insertions are measured in parallel because they compete with or confound precise HDR outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)